Inflammatory gut bacteria that carry proteins structurally similar to myelin, a protective layer surrounding nerve fibers that is damaged in multiple sclerosis (MS), may trigger the development and progression of the disease, according to a new study done in mouse models. The findings may pave the way toward new…
treatment
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to privosegtor, an experimental treatment from Oculis that aims to protect the vision of people experiencing acute optic neuritis. This condition, which involves inflammation of the optic nerve, is a common and often debilitating symptom of…
The balance between two immune signaling molecules — CXCL13 and BAFF — may help identify the hard-to-treat inflammation in the brain and spinal cord that’s thought to be a major driver of disability progression in multiple sclerosis (MS), a study found. The findings may help identify which patients are…
The U.S. Food and Drug Administration (FDA) has approved Scinopharm Taiwan’s glatiramer acetate injection, a generic of Copaxone, to treat multiple sclerosis (MS). Scinopharm is the first pharmaceutical company in Taiwan to win U.S. approval for glatiramer acetate, marking a significant milestone…
The National Institute for Health and Care Excellence (NICE) in England is recommending natalizumab — sold as Tysabri and Tyruko — as an option for certain people with hard-to-control multiple sclerosis (MS). NICE is responsible for deciding which medicines will be covered by the National Health Service…
Tiziana Life Sciences‘ intranasal spray foralumab continues to be safe and well-tolerated, with no drug-related serious side effects reported after long-term use, according to an annual report filed with the U.S. Food and Drug Administration (FDA). The company is developing foralumab for neuroinflammatory diseases such as multiple…
Quantum Biopharma has completed dosing in two toxicology studies requested by the U.S. Food and Drug Administration (FDA) that aim to support the launch of clinical studies of Lucid-MS, an experimental treatment for multiple sclerosis (MS) that’s designed to slow myelin loss. The 180-day toxicity and toxicokinetic…
After months of delay, the U.S. Food and Drug Administration (FDA) has rejected Sanofi‘s application seeking approval of tolebrutinib for the treatment of adults with nonrelapsing secondary progressive multiple sclerosis (MS). While Sanofi announced earlier this month that the decision was likely to be delayed again…
Immutep’s experimental immunotherapy, IMP761, continues to demonstrate a favorable safety profile, along with sustained suppression of T-cell activity, immune cells that are overly active in multiple sclerosis (MS) and other autoimmune diseases. These findings are based on data from healthy people enrolled in an ongoing first-in-human Phase 1…
Relapses in people with relapsing-remitting multiple sclerosis (MS) may be more common in spring and summer, coinciding with warmer temperatures, low humidity, and greater fluctuations in atmospheric pressure, according to a study from Poland. Stressful life events and infections were the most frequent potential relapse triggers, the study found.
In people with progressive multiple sclerosis (MS), treatment with the antioxidant lipoic acid did not improve walking or lessen other symptoms, such as fatigue, but it did show signs of slowing brain atrophy, or the loss of brain tissue. According to the researchers, this suggests possible positive biological…
An enzyme called CEMIP could be a target for small-molecule inhibitors that aim to promote myelin repair in people with multiple sclerosis (MS) and other conditions marked by myelin loss, a study found. Researchers discovered that CEMIP, which is elevated in areas of inflammatory nerve damage in people with…
A clinical trial testing whether music therapy can make botulinum toxin injections for spasticity more tolerable for people with multiple sclerosis (MS) and other neurological conditions is enrolling participants at Clermont-Ferrand University Hospital in France. The study’s protocol was published in PLOS One, in a paper titled, “…
I wrote in the summer about changing the disease-modifying therapy (DMT) for my multiple sclerosis (MS). I’ve familiarized myself with the available DMTs, and I plan to ask my neurologist for her recommendation next week and then make a decision. As I’ve researched my options, I’ve become interested…
Specific disease-modifying therapies (DMTs) significantly slow the rate of brain volume loss in adults with multiple sclerosis (MS), a benefit that is directly linked to reduced long-term disability, according to a new review. A network meta-analysis of more than 26,000 patients confirms that therapies most effective at preserving…
A signaling molecule called erythropoietin (EPO) plays a key role in allowing the immune system to distinguish the body’s own cells from foreign threats, a study found. The findings could lead to new treatments for diseases like multiple sclerosis (MS), in which the immune system inadvertently starts to attack…
The U.S. Food and Drug Administration (FDA) has given tentative approval to Lupin’s Siponimod tablets, a bioequivalent version of Mayzent (siponimod), to treat people with relapsing forms of multiple sclerosis (MS). According to a company press release, the therapy is indicated for use in adults with clinically isolated syndrome,…
A Georgia State University researcher won a $1 million U.S. Department of Veterans Affairs (VA) grant to study whether a program combining cognitive training with exercise can help prevent falls in older adults with multiple sclerosis (MS). “Falls are so common — and frightening — in older adults,” Katherine…
A six-month gluten-free diet significantly eased disability and supported a healthier body composition in women with relapsing-remitting multiple sclerosis (RRMS), a new small study found. The findings support growing evidence linking the gut-brain axis and metabolic inflammation to MS, and suggest that a gluten-free diet may be a promising dietary…
Octave Bioscience is entering into a collaboration with Quest Diagnostics to expand access to its multiple sclerosis disease activity (MSDA) test, which uses data from a set of blood biomarkers to measure how active a patient’s disease is in people with multiple sclerosis (MS). Although the MSDA…
Lynk Pharmaceuticals has received the green light from the U.S. Food and Drug Administration (FDA) to begin clinical trials of its investigational oral therapy LNK01006, which is being developed for multiple sclerosis (MS) and other neuroinflammatory diseases. “We look forward to advancing this promising molecule into human clinical…
For most people with multiple sclerosis (MS), the use of disease-modifying therapies, or DMTs, does not affect their perceived pain, according to a survey-based study in Australia. As few as one-third of MS patients who had ever used DMTs reported a change in pain, while one-eighth of those…
Adherence to either the Mediterranean or the Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diets was associated with better performance in certain areas of thinking and memory among people with multiple sclerosis (MS), a U.K. study suggests. The Mediterranean diet reflects foods traditionally eaten in countries around the Mediterranean Sea.
Aquatic therapy significantly eased fatigue and improved balance in multiple sclerosis (MS) patients in a clinical trial in Greece, outperforming results from a control group who participated in a conventional physiotherapy program. “Our work suggests that incorporating [aquatic therapy] into MS care can meaningfully alleviate fatigue and balance deficits,…
Disability progression is not always permanent for people with relapsing-remitting multiple sclerosis (RRMS), even when it occurs independent of a relapse, a new study has found. Researchers report that nearly one-third of RRMS patients who experience progression independent of relapse activity (PIRA) see their disability levels ease in the…
Oligodendrocytes, the cells that build and repair myelin in the brain and spinal cord, may play a role in the inflammatory processes involved in multiple sclerosis (MS), even at the earliest stages of disease, according to a study in a mouse model. “We found that oligodendrocytes transition to disease…
More than 3 million doses of Vueway (gadopiclenol), a lower-dose gadolinium contrast MRI agent used to diagnose and monitor conditions such as multiple sclerosis (MS), have been administered at more than 900 customer sites, maker Bracco Diagnostics said. Approved by the U.S. Food and Drug Administration for use in children…
A Phase 2 clinical trial testing PIPE-307, an experimental therapy designed to support myelin repair in people with multiple sclerosis (MS), has failed to meet its primary or secondary efficacy goals. The U.S.-based VISTA trial (NCT06083753) enrolled more than 180 adults with relapsing-remitting MS (RRMS). Participants received…
Tyruko (natalizumab-sztn) is now commercially available in the U.S. as the first and only approved biosimilar to Tysabri for adults with relapsing forms of multiple sclerosis (MS). The therapy received approval from the U.S. Food and Drug Administration (FDA) in 2023 for all indications covered by the…
A clinical trial is now recruiting participants to test whether an experimental vaccine for the Epstein-Barr virus (EBV) is safe and may help reduce disease activity in people with multiple sclerosis (MS). The Phase 2 study (NCT06735248) aims to enroll 180 adults, ages 18 to 55, with…